Reactive oxygen species (ROS) are implicated in coronary angiogenesis and collateral growth. In this study, we evaluated the requirement for ROS in endothelial cell (HCAEC) tube formation, coronary collateral development in vivo, and one component of the signaling pathway (redox sensitive p38 MAP kinase) by which ROS may stimulate vascular growth. Administration of the flavin-containing oxidase inhibitor, DPI (10 µM) or the superoxide dismutase (SOD) inhibitor, DETC (10 mM) blocked VEGF-induced (50 ng/ml) endothelial cell (HCAEC) tube formation in Matrigel (p<0.05, n=10). Next, we assessed the effect of DPI and DETC on coronary collateral development in a rat model of episodic ischemia: repetitive occlusion/ischemia (RI) of LAD (40 sec occlusion, every 20 min for 2h20min, 3 times a day, for 10 days). Each day of the protocol, DPI (0.2 mg/kg/day), or DETC (1 g/kg/day) were given by IP injection, or the NAD(P)H oxidase inhibitor, apocynin (0.25 mg/ml) was given in drinking water. Collateral-dependent flow (radioactive microspheres) was expressed as a ratio of flows between the normal and the ischemic zone. In sham animals, collateral flow in the ischemic zone was 18±6% of the normal zone flow; whereas in the RI group collateral flow in the ischemic zone was 83±5% of that in the normal zone. Blockade of ROS (superoxide and H 2 O 2 ) production by DPI prevented the increase in collateral flow after RI (25±4% of that in the normal zone). Nearly identical results were obtained with apocynin following RI (32±7% of that in the normal zone). Increasing superoxide levels and decreasing H 2 O 2 levels by SOD inhibition (DETC) achieved similar results (collateral flow after RI was 21±2% of that in the normal zone). Both DPI and DETC blocked RI-induced p38 MAP kinase activation in response to VEGF in vitro and to RI in vivo. These results demonstrate a requirement for optimal ROS concentration in HCAEC tube formation, coronary collateral development and p38 MAP kinase activation. In addition, p38 MAP kinase inhibition Page 2 of 33 Copyright Information prevented HCAEC tube formation and partially blocked RI-induced coronary collateral development (42±7% of normal zone flow, n=8) indicating that p38 MAP kinase is a critical signaling mediator of coronary collateral growth.
Introduction
Ischemia/reperfusion injury is a biphasic process, in which exposure of the myocardium to prolonged hypoxia/ischemia initiates massive cell death in the affected region of the heart. This is followed by further reperfusion injury commencing upon reestablishment of blood flow and defined as further destruction, including stunning and death, of tissue still alive at the onset of reperfusion.(17) However, under certain conditions, ischemia/reperfusion can lead to adaptive mechanisms that diminish and/or prevent the re-occurrence of injury. Coronary collateral development is an example of such an adaptive response to myocardial ischemia caused by chronic occlusion of major coronary arteries. It has been shown that ischemic preconditioning renders the myocardium tolerant to prolonged ischemia/reperfusion injury(10), in part through promoting collateral development. (4, 16, 20) Our laboratory has previously shown that ROS are critical mediators of coronary collateral development in a canine model of repetitive ischemia. Treatment with N-acetyl cysteine (NAC) attenuated the repetitive ischemia (RI)-induced increase in coronary Both in vitro and in vivo studies suggest that coronary collateral growth is mediated by a highly coordinated signaling cascade. Previously, we have reported a requisite role for vascular endothelial growth factor (VEGF) in coronary collateral growth.(22) VEGF has been shown to activate several signaling pathways including ERK1/2,(21) JNK(17) and p38(6) mitogen activated protein kinases (MAP kinases), the phosphatydilinositol 3-kinase (PI3-kinase)/Akt pathway(5), the non-receptor tyrosine kinases c-Src (7) , focal adhesion kinase (FAK)(30) and Pyk2(13). Of these, p38 MAP kinase(11, 23), Akt(11, 24) and c-Src (25) have been shown to be ROS-sensitive in other cell types.
The potential role of p38 MAP kinase in coronary collateral growth is particularly interesting for a number of reasons. First, p38 MAP kinase has been shown to be specifically activated in response to hypoxia in human cancer cells.(28) Second, HUVEC tube formation in Matrigel was associated with rapid and transient p38 activation(12), and VEGF-induced endothelial cell migration was inhibited by specific p38 MAP kinase inhibition(29), indicating a required and beneficial effect of p38 MAP kinase on endothelial cell tube formation in vitro. The role of p38 MAP kinase has not been investigated in coronary collateral development in vivo. Third, in our preliminary studies, its activation in response to RI was ROS-sensitive, but unlike the activation of other signaling molecules, p38 MAP kinase was only transiently activated.
In this study, we show that an optimal concentration of superoxide and H 2 O 2 allows for HCAEC tube formation in response to VEGF and for coronary collateral growth in response to repetitive ischemia/reperfusion.. Furthermore, we demonstrate, for the first time, that the ROS-sensitive and transient activation of p38 MAP kinase is essential for the underlying positive effect of ROS on stimulating coronary collateral growth.
Materials and Methods
RAT MODEL OF COLLATERAL GROWTH/REPETITIVE ISCHEMIA. 3-4 month old, 300-350 g, male WKY rats were used for chronic (10 days) implantation of a pneumatic occluder over the left anterior descending coronary artery (LAD) as described by Toyota et al (22) . The RI protocol for rat consisted of: 8, 40 sec occlusions, ones every 20 minutes over a duration of 2 hours and 20 minutes followed by a period of "rest" for 5 hours and 40 minutes. This 8 hour cycle was repeated 3 times per day over a period of 10 days. Ru (at end of RI protocol) were injected into the left ventricle over 20 sec. Collateral (LAD)-dependent zone was identified using fluorescence microscopy in which the area without the fluorescent microspheres (injected into the LV at the time of initial surgery while LAD is occluded) is the LADdependent zone. Tissue flow was calculated as a ratio between C m = activity (cpm/g) of the tissue samples from the LAD-dependent and normal zone. All experiments were n=8, and data were analyzed by two-way ANOVA followed by t-test. Collateral flow was measured in the following groups: a sham group (sham) that was instrumented but not subjected to RI (n=8), a control group/RI (n=8), RI + diphenyleneiodonium (DPI, 0.2 mg/kg/day, n=8), RI + apocynin (0.25 mg/ml in drinking water, n=3), and RI + diethyldithiocarbamate (DETC, 1 g/kg/day, n=8). and quantified using NIH Image software. Since none of the treatments altered p38 MAP kinase expression, its total levels were used to check for equal lane loading and to normalize phosphorylation levels. All experiments were performed in triplicate (n=3 animals per group). DATA ANALYSIS. ANOVA followed by t-tests with the Bonferroni Inequality was used to determine statistical analysis. A probability value of P<0.05 was used to determine statistical significance.
MICROSPHERE MEASUREMENTS OF MYOCARDIAL

Results
VEGF-induced HCAEC tube formation requires optimal ROS concentration.
To assess VEGF's ability to induce HCAEC tube formation, cells were seeded on Matrigel at the density of 30,000 cell/well, allowed to attach for 24 hours then treated with VEGF (50 ng/ml). Tube formation was observed after 2 days and was significantly increased in response to VEGF treatment as compared to control, non-treated cells (19±0.02 vs. Treatment with DPI or DETC alone (without VEGF) was not significantly different from control (5±1% and 5±2%, respectively).
Repetitive ischemia causes coronary collateral development in the rat model of repetitive ischemia in vivo.
Results in Figure 2 demonstrate impaired coronary flow in the LAD-dependent (collateral-dependent) zone in animals that underwent a sham surgical procedure, and thus, were not subjected to RI (collateral flow was 18±6% of the normal zone flow and represents native collateral flow, n=8). In contrast, collateral flow in animals that underwent the 10 day RI protocol was 83±5% of that in the normal zone To confirm the effects of ischemia/reperfusion and efficacy of DPI and DETC treatments on superoxide generation in vivo, in some animals DHE was given by LV injection (60 µg/kg) for 20 minutes prior to two consecutive periods of ischemia/reperfusion. Ischemia/reperfusion caused an increase in superoxide generation in the LAD-dependent zone as compared to sham (RI=450±13 vs.
sham=124±6 AU, n=3, p<0.05)( Figure 3A ). When DPI was administered for 2 days prior to DHE injection, superoxide production was markedly lower (RI+DPI=118±9 vs.
RI=450±13 AU, n=3, p<0.05). In contrast, DETC treatment for 2 days resulted in an increase in superoxide concentration above that produced by ischemia/reperfusion (RI+DETC=861±16 vs. RI=450±13 AU, n=3, p<0.05) ( Figure 3A) . Identical results were observed following both one and three consecutive periods of ischemia/reperfusion (data not shown). Furthermore, in some animals CP-H was added and tissue samples were subjected to X-band EPR to obtain a quantitative measurement of superoxide. In all treatment groups the observed superoxide concentrations in the LAD-dependent zone are in precise agreement with the DHE fluorescence intensity (0.12 nM for sham, 0.53 nM for RI, 0.10 nM for RI+DPI, and 1.18 nM for RI+DETC) ( Figure 3B ). Superoxide concentrations in the normal zone were 0.10 nM for sham, 0.36 nM for RI, 0.29 nM for RI+DPI, and 0.64 nM for RI+DETC ( Figure 3B ). Thus, RI increased superoxide concentrations in both the LAD-dependent and the normal zone, but this increase was greater in the LAD-dependent zone. Likewise, the effect of DETC was more pronounced in the LAD-dependent than in the normal zone, while the effect of DPI was pronounced in the LAD-dependent but negligible in the normal zone. Figure 5A shows that p38 is specifically activated (2.7 ± 0.23 fold vs. sham, n=3, p<0.05) in the LAD-dependent region of the myocardium only on day 3 of the RI protocol. This is in contrast to other kinases, including Akt, which remain activated to a high degree for the duration of the protocol (data not shown). This activation is smaller in magnitude than the VEGFinduced response in HCAECs, which likely accounts for a large proportion of cardiac myocytes and fibroblasts in the tissue sample, and a less robust activation of p38 in these cell types vs. in coronary endothelium. In addition, p38 activation by RI was completely blocked by DPI and DETC at the time point of maximal p38 activation by RI (day 3) (Figure 5A ). In a protocol identical to that used for confirmation of DPI and DETC effects on superoxide concentration in vivo, we investigated the effect of these compounds on p38 MAP kinase activation. After 3 days of the RI protocol, animals were sacrificed, hearts excised, LAD-dependent and normal zones separated and prepared for Western blotting. Western blots with phospho-specific anti-p38 antibodies revealed a significant increase in p38 MAP kinase activation in response to ischemia/reperfusion (2.7 ± 0.23 fold vs. sham 1.0 ± 0.17, p<0.05, n=3) in the LAD-dependent zone, which was completely blocked by both DPI and DETC (1.0 ± 0.18 and 1.1 ± 0.3 fold, respectively, p<0.05, n=3) ( Figure 5A) . Expression (total p38 demonstrated by Western blot with anti-p38 MAP kinase antibodies) was not affected by any of the interventions and p38 was not significantly activated in the normal zone (1.2 ± 0.2 fold in RI vs. sham, n=3) ( Figure 5A ).
p38 MAP kinase activation by ischemia/reperfusion is partially responsible for ischemia/reperfusion-induced coronary collateral growth.
To ascertain whether p38 MAP kinase is required for coronary collateral development in response to ischemia/reperfusion in vivo, rats were treated with SB203580 (3.2 mg/kg/day) for the duration of the 10 day RI protocol via IP injection once/day. p38 MAP kinase inhibition resulted in a significant (~50%) decrease in coronary collateral development (42±7% of that in the normal zone, p<0.05, n=8) ( Figure 5B ).
Taken together, these results show that the redox-sensitive p38 MAP kinase is partially responsible for ischemia/reperfusion-induced coronary collateral development, although it remains unclear in which cell type its activation is most important. We confirmed the blockade of p38 MAP kinase by IP administration of SB203580 (3.2 mg/kg/day) in a modified RI protocol (3 days), and found an almost complete (~ 90%) inhibition of the kinase in both the LAD-dependent and the normal zone, while activation of several other kinases, including Akt and ERK1/2, was not effected (data not shown).
Discussion
The major observation of our study is that the induction of endothelial cell tube formation in vitro and coronary collateral growth in vivo require a specific intracellular concentration of ROS. ROS levels below and above (with regards to superoxide) this optimal range prohibit coronary collateral development and endothelial cell tube formation. We also demonstrate that p38 MAP kinase activation plays a pivotal role in ROS signaling for both endothelial cell tube formation, and for the first time, coronary collateral growth in vivo. Our observations and conclusions are supported by some cogent work in the literature.
In support of the present study, it has been reported that short and repetitive exposure to hypoxia/reoxygenation produces ROS that are associated with However, treatment with DPI markedly reduces superoxide concentrations in the heart ( Figure 3A and B), thus potentially increasing or at least not altering NO concentrations. Therefore, we believe that an optimal concentration of superoxide and H 2 O 2 but not NO is critical for coronary collateral growth.
Another proposed explanation for the increase in collateral flow is an increase in coronary dilation in response to ischemia/reperfusion. We doubt that this occurs because coronary circulation is maximally dilated by ischemia. We have confirmed this in a previous study by maximally dilating coronary arteries by dipyridamole during the initial occlusion. Dipyridamole did not increase coronary flow beyond that during occlusion.(22) In addition, in previous work published by our laboratory, micro-CT images clearly show an increase in coronary collateral development following the RI protocol(22). Another point we are compelled to make is that an increase in the collateral-dependent region must reflect collateral growth, i.e, an increase in the caliber of the collateral vessels. The native collateral circulation is high in resistance (collateral flow is 20% of normal zone flow because of the high resistance of these vessels) because of the small caliber of the vessels. Therefore, the only way for flow to quadruple following the RI protocol is through growth of these vessels. p38 MAP kinase has been shown to be redox-dependent in cultured aortic smooth muscle(23) and VEGF has been shown to activate p38 MAP kinase in endothelial cultures(6), but these studies fall short of investigating the redox-sensitivity of p38 MAP kinase in response to VEGF. Here, we show that p38 MAP kinase activation in response to VEGF is ROS-sensitive (Figure 4 Importantly, we show a role for p38 MAP kinase in coronary collateral growth.
Near complete inhibition (>90%) of p38 MAP kinase by SB203580 in vivo lead to a partial (~50%) attenuation in coronary collateral development in response to LAD occlusion ( Figure 5B ). These results demonstrate that collateral growth is partially but critically dependent upon p38 MAP kinase, and indicate that p38 MAP kinase activation in response to RI depends on an optimal level of ROS. Since 80% of cells, by volume, in the whole heart are cardiac myocytes, the observed p38 activation in these preparations is likely to be primarily related to its activation in myocytes. However, p38 activation may be critical in both endothelial cells, where its activation could directly regulate endothelial cell migration, and in cardiac myocytes, where it may affect the expression of growth factors and matrix degrading enzymes to facilitate migration of vascular cells.
Another relevant question is whether regional ischemia is the driving force for coronary collateral growth. In our study, RI induced an increase in myocardial superoxide both in the LAD-dependent and in the normal zone. The increase in superoxide in the normal zone may be related to the myriad observations of remote preconditioning.(19) However, we are compelled to emphasize that superoxide levels generated by RI in the normal zone were lower then those in the LAD-dependent zone.
In addition, the effect of DETC on further increasing superoxide concentrations was far greater in the LAD-dependent then in the normal zone, and the effect of DPI on decreasing superoxide concentrations in the normal zone was negligible. Importantly, p38 MAP kinase activation in the normal zone was not altered by RI. Thus, we believe that while alterations in ROS levels in the remote region of the myocardium may contribute to regulation of coronary collateral growth, regulation of ROS concentrations and especially redox-dependent signaling in the ischemic zone is more significant.
The novel findings in this study, specifically, the demonstration of a requirement for a specific concentration range of ROS for coronary collateral growth, and the partial but definitive dependence of coronary collateral growth on p38 MAP kinase, provide an important step towards understanding the molecular mechanisms that regulate coronary collateral growth. 
